An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer

Trial Profile

An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2017

At a glance

  • Drugs Folitixorin (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Isofol Medical
  • Most Recent Events

    • 31 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
    • 24 Aug 2017 According to an Isofol Medical media release, to date 38 patients with metastatic colorectal cancer have been treated in the study.
    • 24 Aug 2017 Results presented in an Isofol Medical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top